FindTrial
Sign In

Studying How Certain Genes Affect the Success of Medications (Buprenorphine and Naloxone) for Opioid Addiction Treatment

Genetic polymorphism and treatment outcomes in opioid use disorder patients: A study of OPRD1 and OPRM1 variants in Buprenorphine and Naloxone pharmacotherapy - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2024/02/063348
Enrollment
300
Registered
2024-02-29
Start date
Unknown
Completion date
Unknown
Last updated
2024-03-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: F112- Opioid dependence

Interventions

Intervention1: NIL: NIL Control Intervention1: NIL: NIL

Sponsors

PGIMER, Chandigarh
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Age: 18-65 years, Either gender, Diagnosis of moderate or severe OUD as per DSM-V criteria or opioid dependence as per ICD-11, Providing written informed consent, Participants within a week of initiating buprenorphine naloxone (BNX) treatment.

Exclusion criteria

Exclusion criteria: Presence of cardiomyopathy, Patients with liver disease

Design outcomes

Primary

MeasureTime frame
Treatment retention- time in weeks until buprenorphine/naloxone treatment discontinuationTimepoint: assessed every week—

Secondary

MeasureTime frame
Proportion of negative urine screen for opioids other than buprenorphine, Mean daily dose of buprenorphine(buprenorphine and naloxone), Adverse effects associated with buprenorphine Timepoint: assessed every month—

Countries

India

Contacts

Public ContactAdarsh M V

Post graduate institute of medical education and research, Chandigarh

drbikashus@yahoo.com9914207510

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026